We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-12.12%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.23B
AUM Growth
-$138M
Cap. Flow
+$87.1M
Cap. Flow %
7.07%
Top 10 Hldgs %
28.99%
Holding
134
New
17
Increased
54
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
STJ
St Jude Medical
STJ
+$37.8M
2
AET
Aetna Inc
AET
+$26.5M
3
ACHC icon
Acadia Healthcare
ACHC
+$23.1M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$21.1M
5
CHMA
Chiasma, Inc. Common Stock
CHMA
+$13M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$42.2M
2
HUM icon
Humana
HUM
+$25.2M
3
THOR
THORATEC CORPORATION
THOR
+$24.5M
4
BHC icon
Bausch Health
BHC
+$17.9M
5
MCK icon
McKesson
MCK
+$16.8M

Sector Composition

Rank Sector Weight
1 Healthcare 76.04%
2 Financials 3.43%
3 Technology 0.48%
4 Industrials 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
76
BioMarin Pharmaceuticals
BMRN
$12.4B
$5.32M 0.43%
50,500
+18,000
+55% +$2.4M
CO
77
DELISTED
Global Cord Blood Corporation
CO
$5.3M 0.43%
880,000
+50,000
+6% +$311K
REGN icon
78
Regeneron Pharmaceuticals
REGN
$80.8B
$5.12M 0.42%
11,000
– –
KITE
79
DELISTED
Kite Pharma, Inc.
KITE
$5.09M 0.41%
91,500
-26,500
-22% -$1.67M
ATHN
80
DELISTED
Athenahealth, Inc.
ATHN
$5.07M 0.41%
38,000
– –
AIMT
81
DELISTED
Aimmune Therapeutics
AIMT
$5.06M 0.41%
+200,000
New +$4.68M
NVAX icon
82
Novavax
NVAX
$1.31B
$5.05M 0.41%
35,750
– –
ASND icon
83
Ascendis Pharma A/S
ASND
$16.8B
$4.78M 0.39%
270,000
+30,000
+13% +$584K
TNDM icon
84
Tandem Diabetes Care
TNDM
$1.56B
$4.78M 0.39%
54,250
+750
+1% +$87.3K
AGN.PRA
85
DELISTED
Allergan plc
AGN.PRA
$4.73M 0.38%
5,000
– –
MGNX icon
86
MacroGenics
MGNX
$257M
$4.67M 0.38%
218,000
+80,500
+59% +$2.53M
RLYP
87
DELISTED
RELYPSA INC COM
RLYP
$4.67M 0.38%
252,000
+11,900
+5% +$327K
TXMD icon
88
TherapeuticsMD
TXMD
$24M
$4.54M 0.37%
+15,500
New +$5.51M
GNCA
89
DELISTED
Genocea Biosciences, Inc.
GNCA
$4.45M 0.36%
+81,250
New +$8.06M
CSLT
90
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$4.2M 0.34%
1,000,000
+200,000
+25% +$1.26M
KYNB
91
Kyntra Bio
KYNB
$29.4M
$4.17M 0.34%
7,600
– –
PETX
92
DELISTED
Aratana Therapeutics, Inc.
PETX
$4.1M 0.33%
485,000
+185,000
+62% +$3.13M
ATYR
93
aTyr Pharma
ATYR
$50.1M
$3.99M 0.32%
27,785
-1,393
-5% -$318K
EPZM
94
DELISTED
Epizyme, Inc
EPZM
$3.99M 0.32%
310,000
+3,500
+1% +$70.6K
EGLT
95
DELISTED
Egalet Corporation
EGLT
$3.95M 0.32%
+300,000
New +$3.81M
BLUE
96
DELISTED
bluebird bio
BLUE
$3.85M 0.31%
3,474
– –
NVTA
97
DELISTED
Invitae Corporation
NVTA
$3.68M 0.3%
510,000
+110,000
+28% +$1.16M
DVAX
98
DELISTED
Dynavax Technologies
DVAX
$3.68M 0.3%
+150,000
New +$4.25M
ASMB icon
99
Assembly Biosciences
ASMB
$529M
$3.55M 0.29%
30,917
+4,792
+18% +$843K
CDTX
100
DELISTED
Cidara Therapeutics
CDTX
$3.5M 0.28%
13,750
+1,250
+10% +$357K
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, Rock Springs Capital Management held 134 positions worth $1.23B, down 10% from $1.37B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $87.1M of net new capital in Q3 2015, opening 17 new positions and adding to 54 existing holdings. Its largest new stake was St Jude Medical: 530,000 shares worth $33.4M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 77% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was THORATEC CORPORATION, an estimated $24.5M trimmed.

  • Rock Springs Capital Management's largest Q3 2015 buy was St Jude Medical: 530,000 shares worth $33.4M.
  • Rock Springs Capital Management added most to Aetna Inc in Q3 2015, an estimated $26.5M increase.
  • Rock Springs Capital Management's biggest Q3 2015 reduction was THORATEC CORPORATION, cutting an estimated $24.5M.
  • Rock Springs Capital Management fully exited Medtronic in Q3 2015, selling an estimated $42.2M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $1.23B portfolio in Q3 2015.
  • Rock Springs Capital Management opened 17 new positions and closed 13 in Q3 2015.
  • Rock Springs Capital Management's portfolio value fell 10% quarter-over-quarter to $1.23B.

Based on Rock Springs Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.